Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

287 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 20-07-2020 | COVID-19 | News | Article

    COVID-19 risk factors described for patients undergoing active anticancer treatment

    Carlos Gómez-Martin and colleagues, from the Hospital Universitario 12 de Octubre in Madrid, Spain, screened 287 cancer patients for SARS-CoV-2 between 9 March and 19 April 2020, 63 of whom were admitted to hospital with COVID-19.

    Author:
    Hannah Kitt
    Published in:
    Eur J Cancer 2020; doi:10.1016/j.ejca.2020.06.001
  2. 20-06-2019 | Non-small-cell lung cancer | News | Article

    Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

    Participants were randomly allocated to receive maintenance therapy every 3 weeks with either bevacizumab 15 mg/kg (n=287), pemetrexed 500 mg/m 2 (n=294), or the combination (n=293), and were followed up for a median of 60 months.

    Published in:
    2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June
  3. 03-09-2018 | Advanced breast cancer | News | Article

    EMBRACA results demonstrate talazoparib advanced breast cancer benefits

    Median PFS was 8.6 months for the 287 patients randomly assigned to receive open-label talazoparib 1 mg/day compared with a median PFS of 5.6 months for the 144 patients who instead received physician’s choice of single-agent therapy with capecitabine, eribulin, gemcitabine, or vinorelbine.

    Published in:
    N Engl J Med 2018; 379 : 753–763 Ann Oncol 2018; doi:10.1093/annonc/mdy257
  4. 14-02-2018 | Non-small-cell lung cancer | News | Article

    Nivolumab offers durable survival benefits in advanced NSCLC

    At 3 years, seven (5%) of 131 patients with squamous NSCLC and 19 (7%) of 287 with nonsquamous NSCLC were still receiving treatment with nivolumab, compared with none of those assigned to use docetaxel.

    Published in:
    Ann Oncol 2018; Advance online publication
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.